Glaukos Corporation $GKOS Shares Purchased by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd grew its stake in shares of Glaukos Corporation (NYSE:GKOS) by 10.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 449,846 shares of the medical instruments supplier’s stock after purchasing an additional 43,750 shares during the quarter. AustralianSuper Pty Ltd owned approximately 0.78% of Glaukos worth $36,685,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of GKOS. Smartleaf Asset Management LLC raised its stake in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares in the last quarter. UMB Bank n.a. increased its position in shares of Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the last quarter. State of Wyoming boosted its position in shares of Glaukos by 13.1% in the 3rd quarter. State of Wyoming now owns 1,723 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 199 shares during the period. Finally, Amalgamated Bank boosted its position in shares of Glaukos by 1.5% in the 3rd quarter. Amalgamated Bank now owns 16,238 shares of the medical instruments supplier’s stock valued at $1,324,000 after purchasing an additional 242 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. The Goldman Sachs Group reissued a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Stephens upped their target price on shares of Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 2nd. Finally, UBS Group increased their target price on shares of Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Insider Activity

In other news, CEO Thomas William Burns sold 186,945 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the sale, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. This represents a 54.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the sale, the director owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This represents a 28.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 325,000 shares of company stock worth $37,739,259 in the last quarter. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Trading Down 2.9%

Shares of GKOS stock opened at $117.63 on Wednesday. The stock has a market cap of $6.83 billion, a P/E ratio of -36.08 and a beta of 0.70. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The business has a fifty day simple moving average of $116.12 and a 200-day simple moving average of $100.55.

Glaukos (NYSE:GKOS) last announced its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The business had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The business’s revenue was up 35.6% on a year-over-year basis. On average, analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.